The Fort Worth Press - Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

USD -
AED 3.672501
AFN 63.999821
ALL 82.253977
AMD 360.510128
ANG 1.790403
AOA 917.498737
ARS 1552.758602
AUD 1.483977
AWG 1.8025
AZN 1.699803
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.796998
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.429745
CDF 2317.999928
CHF 0.841035
CLF 0.02537
CLP 998.480068
CNY 6.66455
CNH 6.666355
COP 3314.81
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.18105
DJF 178.098271
DKK 6.79992
DOP 60.559465
DZD 137.08899
EGP 53.689599
ERN 15
ETB 164.140883
EUR 0.90965
FJD 2.296797
FKP 0.758367
GBP 0.75805
GEL 2.595013
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.502912
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 333.008502
IDR 18270.5
ILS 3.24803
IMP 0.758367
INR 93.48355
IQD 1516.079284
IRR 1925253.999459
ISK 124.44977
JEP 0.758367
JMD 158.919789
JOD 0.708989
JPY 159.399503
KES 129.999947
KGS 87.449019
KHR 4080.072793
KMF 447.497235
KPW 900.00035
KRW 1336.402706
KWD 0.31172
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 56.069019
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.859893
MVR 15.409893
MWK 1734.212921
MXN 18.486875
MYR 4.094503
MZN 63.910141
NAD 16.918528
NGN 1349.369821
NIO 36.80602
NOK 9.625225
NPR 149.481136
NZD 1.81936
OMR 0.384508
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.6585
PKR 276.505202
PLN 4.00316
PYG 6230.864068
QAR 3.64562
RON 4.865802
RSD 107.022012
RUB 82.04668
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.879028
SDG 601.49862
SEK 10.126925
SGD 1.288895
SHP 0.758581
SLE 23.050416
SLL 20969.503664
SOS 571.501363
SRD 37.43798
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.834502
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.417602
TTD 6.771395
TWD 32.941978
TZS 2650.003004
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603604
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.691317
XAG 0.02097
XAU 0.000259128447
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.691317
XPF 108.509428
YER 236.503383
ZAR 16.94351
ZMK 9001.198726
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.073939
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -

- Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 -

- Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET -

Text size:

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company's GMP manufacturing facility is available for viewing via slideshow on the Presentations page of the Investor Relations portion of the Company's website. The Company's Form 10-K can be viewed on the SEC Filings page.

Concurrently, the Company announced a strategic restructuring of its business operations to focus its resources on manufacturing critical starting materials for genetic medicines enabled by its Linea™ DNA and Linea™ IVT platforms. Ongoing and future actions supporting Applied DNA's restructuring strategy include:

  • The pursuit of a divestiture of the CertainT® platform for supply chain traceability and authentication1;

  • The targeting of operating expense reductions of 15% compared to fiscal 2024, inclusive of costs associated with the potential divestiture of the CertainT platform. Cost reductions are expected to be completed in the second quarter of fiscal 2025 (ending March 31, 2025);

  • The retention of Applied DNA Clinical Labs, the Company's clinical laboratory subsidiary, which will pursue profitable growth via its TR8™ pharmacogenomic (PGx) testing services; and

  • The immediate promotion of Chief Operating Officer Judith Murrah to President. Chief Legal Officer and Executive Director of Business Development Clay Shorrock assumes the additional role of President of LineaRx, Inc., the Company's majority-owned enzymatic DNA manufacturing subsidiary. Dr. James A. Hayward remains Chairman of the Board of Directors and Chief Executive Officer.

  • Retention of its non-GMP DNA manufacturing business for in vitro diagnostics (IVD) and other specialty applications.

Management Commentary
"Following a thorough review of our businesses to enhance value for shareholders, we believe that our expertise and experience in enzymatic DNA production, the wealth of data generated over years that validate Linea DNA as a compelling alternative to plasmid DNA, and our proximity to GMP manufacturing is not fully recognized in our current structure. Our actions today will sharpen our focus on commercialization initiatives for our Linea DNA and Linea IVT platforms to return the Company to revenue growth and expand shareholder value," stated Dr. Hayward. "With several of our existing customers expected to initiate clinical trials in the next twelve months, we believe the completion of our GMP manufacturing facility will allow us to win several long-term, high-margin GMP supply agreements for IVT templates, resulting in the significant utilization of our GMP manufacturing capacity in FY2025."

Recent Operational Highlights
Therapeutic DNA Production Services (LineaRx)
GMP roadmap execution:

  • The buildout of the Company's GMP manufacturing facility is expected to be completed by January 9, 2025, with an annual revenue capacity ranging between $4 million and $16 million depending on product mix (sales of Linea DNA or the paired-Linea DNA IVT template-and-Linea RNA polymerase for mRNA production)2.

Linea DNA/Linea IVT template commercialization:

  • GMP production runs are expected to begin in the first half of CY2025 to supply Linea DNA IVT templates to existing customers for the manufacture of mRNA clinical trial materials.

  • Initiated a development program with a well-known enzyme engineering company for a next-generation high fidelity, long-range DNA polymerase (DNAP) and buffer system to amplify long and complex DNA sequences via PCR. The resultant DNAP/buffer system combination will be exclusive to LineaRx and will allow for greater efficiencies and sequence fidelity in the manufacture of Linea DNA of >6kb in length.

  • The Linea IVT platform (paired IVT template and RNA polymerase) is being evaluated by a multinational pharmaceuticals manufacturer in Japan.

Linea DNA commercialization for IVT diagnostics:

  • Received a $500,000 follow-on order from a global manufacturer of IVDs for a cancer diagnostic application.

MDx Testing Services (Applied DNA Clinical Labs)
TR8 PGx testing service commercialization:

  • Applied DNA Clinical Labs (ADCL), the Company's clinical molecular diagnostics and genetic testing services subsidiary, is presently exploring reference lab opportunities for volume-based testing. ADCL continues to refine its go-to-market strategy for its precision medicine approach to personalized prescribing.

________________________________

1 While the Company is currently in negotiations for the potential divestiture of the CertainT platform, no assurance can be given that a potential divestiture will be completed.

2 Based on internal company assumptions and modeling using a 1/100 DNA-to-RNA amplification ratio and an mRNA vaccine dose of 30μg. Manufacture of the final mRNA drug substance will be conducted by therapy developers or their CDMO.

Financial Highlights
Total revenues for the fourth quarter of fiscal 2024 were $813 thousand compared with $780 thousand for the same period of fiscal 2023. The year-over-year increase was a result of higher Service revenues primarily related to an increase in isotopic testing services revenues that offset lower clinical laboratory services revenues due to a decrease in demand for COVID-19 testing.

Operating loss for the fourth quarter of fiscal 2024 was $3.3 million compared with $4.2 million in the prior year period. The improvement is primarily attributable to lower selling, general and administrative costs year-over-year attributable to lower stock-based compensation, offset by an increase in professional fees.

Net loss for the fourth quarter of fiscal 2024 was $3.3 million, or $0.32 per share, compared with $3.6 million, or $5.29 per share, in the prior year period and on a higher number of shares outstanding. Adjusted EBITDA for the fourth quarter of fiscal 2024 was a negative $3.2 million compared with a negative $3.5 million in the prior year period.

Total revenues for fiscal 2024 were $3.4 million compared with $13.4 million in fiscal 2023. The decrease was driven by lower clinical laboratory services revenues due to a decrease in demand for COVID-19 testing services, as the prior fiscal year included testing revenues under our contract with CUNY, which terminated in June 2023.

Operating loss for fiscal 2024 was $14.0 million compared with $11.0 million in the prior year period. The increase was driven primarily by lower clinical laboratory services revenues, offset by a decrease in total operating expenses.

Net loss for fiscal 2024 was $7.1 million, or $1.82 per share, compared with $10.0 million, or $15.21 per share in the prior year period and on a higher number of shares outstanding.

Cash and cash equivalents on September 30, 2024, totaled $6.4 million. On October 31, 2024, the Company completed a registered direct offering and received net proceeds of approximately $5.8 million after deducting placement agent fees and other estimated offering costs payable by the Company. As a result of this offering, cash and cash equivalents as of November 3, 2024, were approximately $10.1 million.

January 9 Investor Update Conference Call Information

The Company will hold a conference call and webcast to update investors on its restructuring and GMP roadmap on January 9, 2025, at 4:30 PM ET. To participate in the conference call, please follow the instructions below. While every attempt will be made to answer investors' questions on the Q&A portion of the call, not all questions may be answered.

To participate, please ask to be joined to the 'Applied DNA Sciences' call:

  • Domestic callers (toll free): 844-887-9402

  • International callers: 412-317-6798

  • Canadian callers (toll free): 866-605-3852

Live and replay of webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=3UkskFxG

Telephonic replay (available 1 hour following the conclusion of the live call through January 16, 2025):

  • Domestic callers (toll free): 1-877-344-7529

  • Canadian callers (toll free): 1-855-669-9658

  • Participant Passcode: 7896562

An accompanying slide presentation that will be embedded in the webcast can be accessed under 'News & Events' tab and 'Company Events' section of the Applied DNA investor relations website at https://investors.adnas.com/

Information about Non-GAAP Financial Measures

As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core businesses. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our businesses by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

"EBITDA"- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

"Adjusted EBITDA"- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation and the potential to achieve that goal, the future success of its Linea DNA and Linea IVT platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, the unknown amount of revenues and profits that will result from its TR8 PGx testing service, the unknown outcome of the potential divestiture of the Company's CertainT Platform, and if successfully divested, the unknown consideration that will be received by the Company, the limited market acceptance for its CertainT Platform, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 7, 2023, its Quarterly Reports on Form 10-Q filed on February 8, 2024, May 10, 2024, August 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]
Web: www.adnas.com
X: @APDN

- Financial Tables Follow -

APPLIED DNA SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS

September 30,

September 30,

2024

2023

ASSETS
Current assets:
Cash and cash equivalents

$

6,431,095

$

7,151,800

Accounts receivable, net of allowance for credit losses of $75,000 at September 30, 2024 and 2023

362,013

255,502

Inventories

438,592

330,027

Prepaid expenses and other current assets

815,970

389,241

Total current assets

8,047,670

8,126,570

Property and equipment, net

553,233

838,270

Other assets:
Restricted cash

750,000

750,000

Intangible assets

2,698,975

2,698,975

Operating right of use asset

739,162

1,237,762

Total assets

$

12,789,040

$

13,651,577

LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities

$

1,793,427

$

2,270,388

Operating lease liability, current

545,912

498,598

Deferred revenue

58,785

76,435

Total current liabilities

2,398,124

2,845,421

Long term accrued liabilities

31,467

31,467

Deferred revenue, long term

194,000

194,000

Operating lease liability, long term

193,249

739,162

Deferred tax liability, net

684,115

684,115

Warrants classified as a liability

320,000

4,285,000

Total liabilities

3,820,955

8,779,165

Commitments and contingencies
Applied DNA Sciences, Inc. stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2024 and 2023

-

-

Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of September 30, 2024 and 2023

-

-

Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of September 30, 2024 and 2023

-

-

Common stock, par value $0.001 per share; 200,000,000 shares authorized as of September 30, 2024 and 2023, 10,311,885 and 682,926 shares issued and outstanding as of September 30, 2024 and 2023, respectively

10,314

683

Additional paid in capital

318,805,058

307,397,623

Accumulated deficit

(309,672,755

)

(302,447,147

)

Applied DNA Sciences, Inc. stockholders' equity

9,142,617

4,951,159

Noncontrolling interest

(174,532

)

(78,747

)

Total equity

8,968,085

4,872,412

Total liabilities and equity

$

12,789,040

$

13,651,577

APPLIED DNA SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

Three Month Period Ended

Twelve Month Period Ended

September 30,

September 30,

2024

2023

2024

2023

(unaudited)

(unaudited)

Revenues
Product revenues

$

127,727

$

87,385

$

1,074,813

$

1,218,185

Service revenues

359,899

170,053

1,038,677

996,866

Clinical laboratory service revenues

325,480

522,298

1,317,930

11,152,392

Total revenues

813,106

779,736

3,431,420

13,367,443

Cost of product revenues

285,616

204,777

1,138,650

1,308,620

Cost of clinical laboratory service revenues

282,591

495,963

1,275,891

6,525,391

Total cost of revenues

568,207

700,740

2,414,541

7,834,011

Operating expenses:
Selling, general and administrative

2,684,444

3,310,910

11,447,894

12,751,644

Research and development

831,711

938,907

3,593,750

3,735,078

Total operating expenses

3,516,155

4,249,817

15,041,644

16,486,722

LOSS FROM OPERATIONS

(3,271,256

)

(4,170,821

)

(14,024,765

)

(10,953,290

)

Interest income

91,329

41,224

176,301

75,332

Unrealized (loss) gain on change in fair value of warrants

(134,000

)

519,700

9,430,000

854,400

Unrealized (loss) on change in fair value of warrants - warrant modifications

-

-

(394,000

)

-

Transaction costs related to warrant liabilities

-

-

(633,198

)

-

Loss on issuance of warrants

-

(1,633,767

)

-

Other income (expense), net

183

(5,754

)

(8,877

)

642

NET LOSS

$

(3,313,744

)

$

(3,615,651

)

$

(7,088,306

)

$

(10,022,916

)

Less: Net loss attributable to noncontrolling interest

$

17,000

$

23,387

$

95,785

$

75,857

Deemed dividend warrant repricing

$

-

$

-

$

(233,087

)

$

-

Net loss applicable to common stockholders

$

(3,296,744

)

$

(3,592,264

)

$

(7,225,608

)

$

(9,947,059

)

Net loss per share-basic and diluted

$

(0.32

)

$

(5.29

)

$

(1.82

)

$

(15.21

)

Weighted average shares outstanding- basic and diluted

10,301,831

678,442

3,966,026

653,771

APPLIED DNA SCIENCES, INC.
CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA
(unaudited)

Three Month Period Ended September 30,

2024

2023

Net loss

$

(3,313,744

)

$

(3,615,651

)

Interest income

(91,329

)

(41,224

)

Depreciation and amortization

76,985

329,681

Provision for bad debt

(6,089

)

16,810

Stock based compensation expense

30,248

341,495

Unrealized loss (gain) on change in fair value of warrants classified as a liability

134,000

(519,700

)

Share issuance Spindle earnout

17,125

-

Total non-cash items

160,940

127,062

Consolidated Adjusted EBITDA (loss)

$

(3,152,804

)

$

(3,488,589

)

SOURCE: Applied DNA Sciences

H.M.Hernandez--TFWP